Emergence of simian immunodeficiency virus-specific cytotoxic CD4 + T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus

Journal of Immunology

Volumn 185, Issue 6, 2010, Pages 3348-3358

  Von Gegerfelt, Agneta ^a   Valentin, Antonio ^a   Alicea, Candido ^a   Van Rompay, Koen K A ^b   Marthas, Marta L ^b   Montefiori, David C ^c   Pavlakis, George N ^a   Felber, Barbara K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS ANTIGEN; GRANZYME B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GENES, ENV; LYMPHOCYTE DEPLETION; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; UP-REGULATION; VACCINES, ATTENUATED; VIREMIA; VIRUS REPLICATION;

EID: 78649843409     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000572     Document Type: Article

References (67)

1. Koff, W. C., P. R. Johnson, D. I. Watkins, D. R. Burton, J. D. Lifson, K. J. Hasenkrug, A. B. McDermott, A. Schultz, T. J. Zamb, R. Boyle, and R. C. Desrosiers. 2006. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 7: 19-23.
2. Whitney, J. B., and R. M. Ruprecht. 2004. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 17: 17-26.
3. Blancou, P., N. Chenciner, R. Ho Tsong Fang, V. Monceaux, M. C. Cumont, D. Guétard, B. Hurtrel, and S. Wain-Hobson. 2004. Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus. J. Virol. 78: 1080-1092.
4. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72: 1431-1437.
5. Fultz, P. N., P. J. Vance, M. J. Endres, B. Tao, J. D. Dvorin, I. C. Davis, J. D. Lifson, D. C. Montefiori, M. Marsh, M. H. Malim, and J. A. Hoxie. 2001. In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J. Virol. 75: 278-291.
6. Gibbs, J. S., D. A. Regier, and R. C. Desrosiers. 1994. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10: 607-616.
7. Guan, Y., J. B. Whitney, M. Detorio, and M. A. Wainberg. 2001. Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted. J. Virol. 75: 4056-4067.
8. Guan, Y., J. B. Whitney, C. Liang, and M. A. Wainberg. 2001. Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences. J. Virol. 75: 2776-2785.
9. Kestler, H. W., D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662.
10. Shacklett, B. L., K. E. Shaw, L. A. Adamson, D. T. Wilkens, C. A. Cox, D. C. Montefiori, M. B. Gardner, P. Sonigo, and P. A. Luciw. 2002. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J. Virol. 76: 11365-11378.
11. von Gegerfelt, A., and B. K. Felber. 1997. Replacement of posttranscriptional regulation in SIVmac239 generated a Rev-independent infectious virus able to propagate in rhesus peripheral blood mononuclear cells. Virology 232: 291-299.
12. von Gegerfelt, A. S., C. Alicea, A. Valentin, M. Morrow, K. K. van Rompay, M. Ayash-Rashkovsky, P. Markham, J. G. Else, M. L. Marthas, G. N. Pavlakis, et al. 2006. Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res. Hum. Retroviruses 22: 516-528.
13. von Gegerfelt, A. S., V. Liska, P. L. Li, H. M. McClure, K. Horie, F. Nappi, D. C. Montefiori, G. N. Pavlakis, M. L. Marthas, R. M. Ruprecht, and B. K. Felber. 2002. Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. J. Virol. 76: 96-104.
14. - simian immunodeficiency virus SIVmac239: replication kinetics and genomic stability. J. Virol. 73: 6159-6165.
15. - human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J. Virol. 68: 7944-7952.
16. Bray, M., S. Prasad, J. W. Dubay, E. Hunter, K. T. Jeang, D. Rekosh, and M. L. Hammarskjöld. 1994. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc. Natl. Acad. Sci. USA 91: 1256-1260.
17. Tabernero, C., A. S. Zolotukhin, J. Bear, R. Schneider, G. Karsenty, and B. K. Felber. 1997. Identification of an RNA sequence within an intracisternal-A particle element able to replace Rev-mediated posttranscriptional regulation of human immunodeficiency virus type 1. J. Virol. 71: 95-101.
18. Tabernero, C., A. S. Zolotukhin, A. Valentin, G. N. Pavlakis, and B. K. Felber. 1996. The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function. J. Virol. 70: 5998-6011.
19. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N. Pavlakis. 1989. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86: 1495-1499.
20. Hadzopoulou-Cladaras, M., B. K. Felber, C. Cladaras, A. Athanassopoulos, A. Tse, and G. N. Pavlakis. 1989. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. Virol. 63: 1265-1274.
21. D'Agostino, D. M., B. K. Felber, J. E. Harrison, and G. N. Pavlakis. 1992. The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. Mol. Cell. Biol. 12: 1375-1386.
22. Baba, T. W., Y. S. Jeong, D. Pennick, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267: 1820-1825.
23. Baba, T. W., V. Liska, A. H. Khimani, N. B. Ray, P. J. Dailey, D. Penninck, R. Bronson, M. F. Greene, H. M. McClure, L. N. Martin, and R. M. Ruprecht. 1999. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5: 194-203.
24. Johnson, R. P., J. D. Lifson, S. C. Czajak, K. S. Cole, K. H. Manson, R. Glickman, J. Yang, D. C. Montefiori, R. Montelaro, M. S. Wyand, and R. C. Desrosiers. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73: 4952-4961.
25. Shibata, R., C. Siemon, S. C. Czajak, R. C. Desrosiers, and M. A. Martin. 1997. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71: 8141-8148.
26. Tenner-Racz, K., C. Stahl Hennig, K. Uberla, H. Stoiber, R. Ignatius, J. Heeney, R. M. Steinman, and P. Racz. 2004. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc. Natl. Acad. Sci. USA 101: 3017-3022.
27. Wyand, M. S., K. Manson, D. C. Montefiori, J. D. Lifson, R. P. Johnson, and R. C. Desrosiers. 1999. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73: 8356-8363.
28. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189: 991-998.
29. + T cells to containment of viral replication and emergence of mutations in Mamu-A*01-restricted epitopes in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 82: 5631-5635.
30. + lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75: 10187-10199.
31. + cell depletion amplifies the acute retroviral syndrome. J. Neurovirol. 10(Suppl. 1): 58-66.
32. Matano, T., R. Shibata, C. Siemon, M. Connors, H. C. Lane, and M. A. Martin. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72: 164-169.
33. + T cell proliferation that contributes to increased viral loads. J. Immunol. 183: 5006-5012.
34. + lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239-delta3-vaccinated rhesus macaques. J. Virol. 79: 8131-8141.
35. + lymphocytes. Science 283: 857-860.
36. + lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154: 1923-1932.
37. + lymphocyte-depleted simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 82: 5618-5630.
38. + T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 191: 1921-1931.
39. + T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. J. Gen. Virol. 86: 3375-3384.
40. + cells in controlling replication of non-pathogenic simian immunodeficiency virus SIVmac1A11. Virol. J. 3: 22-26.
41. Suryanarayana, K., T. A. Wiltrout, G. M. Vasquez, V. M. Hirsch, and J. D. Lifson. 1998. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res. Hum. Retroviruses 14: 183-189.
42. Rosati, M., A. Valentin, R. Jalah, V. Patel, A. von Gegerfelt, C. Bergamaschi, C. Alicea, D. Weiss, J. Treece, R. Pal, et al. 2008. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26: 5223-5229.
43. Montefiori, D. C. 2005. Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. Curr. Protoc. Immunol. 64:12.11.1-12.11.17.
44. Felber, B. K., A. S. Zolotukhin, and G. N. Pavlakis. 2007. Posttranscriptional control of HIV-1 and other retroviruses and its practical applications. Adv. Pharmacol. 55: 161-197.
45. Grüter, P., C. Tabernero, C. von Kobbe, C. Schmitt, C. Saavedra, A. Bachi, M. Wilm, B. K. Felber, and E. Izaurralde. 1998. TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol. Cell 1: 649-659.
46. Bernstein, H. B., A. L. Kinter, R. Jackson, and A. S. Fauci. 2004. Neonatal natural killer cells produce chemokines and suppress HIV replication in vitro. AIDS Res. Hum. Retroviruses 20: 1189-1195.
47. Oliva, A., A. L. Kinter, M. Vaccarezza, A. Rubbert, A. Catanzaro, S. Moir, J. Monaco, L. Ehler, S. Mizell, R. Jackson, et al. 1998. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102: 223-231.
48. + lymphocytes from HIV-2-infected baboons. Immunol. Lett. 66: 151-157.
49. + cells involves a noncytotoxic mechanism. J. Virol. 65: 5921-5927.
50. + T lymphocytes from macaques immunized with live attenuated SIV. J. Virol. 72: 6315-6324.
51. + lymphocyte depletion but does not account for accelerated SIV pathogenesis. J. Exp. Med. 206: 1575-1588.
52. Neville, D. M., Jr., J. Scharff, H. Z. Hu, K. Rigaut, J. Shiloach, W. Slingerland, and M. Jonker. 1996. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J. Immunother. Emphasis Tumor Immunol. 19: 85-92.
53. Mansfield, K., S. M. Lang, M. C. Gauduin, H. B. Sanford, J. D. Lifson, R. P. Johnson, and R. C. Desrosiers. 2008. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J. Virol. 82: 4135-4148.
54. Almond, N., T. Corcoran, R. Hull, B. Walker, J. Rose, R. Sangster, K. Silvera, P. Silvera, M. Cranage, E. Rud, and E. J. Stott. 1997. Mechanisms of protection induced by attenuated simian immunodeficiency virus. IV. Protection against challenge with virus grown in autologous simian cells. J. Med. Primatol. 26: 34-43.
55. Langlois, A. J., R. C. Desrosiers, M. G. Lewis, V. N. KewalRamani, D. R. Littman, J. Y. Zhou, K. Manson, M. S. Wyand, D. P. Bolognesi, and D. C. Montefiori. 1998. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J. Virol. 72: 6950-6955.
56. + lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6: e1000747.
57. + T-cell suppression of SIV viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6: e1000748.
58. Shresta, S., C. T. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10: 581-587.
59. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
60. + CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J. Immunol. 156: 153-159.
61. + T cells. J. Immunol. 159: 2091-2099.
62. Jellison, E. R., S. K. Kim, and R. M. Welsh. 2005. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J. Immunol. 174: 614-618.
63. Landais, E., X. Saulquin, E. Scotet, L. Trautmann, M. A. Peyrat, J. L. Yates, W. W. Kwok, M. Bonneville, and E. Houssaint. 2004. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103: 1408-1416.
64. Stuller, K. A., and E. Flaño. 2009. CD4 T cells mediate killing during persistent gammaherpesvirus 68 infection. J. Virol. 83: 4700-4703.
65. +, cytotoxic phenotype in an HIV-1 long-term non-progressor and in CMV infection. Blood 103: 2238-2247.
66. + T lymphocytes with cellular maturation. J. Exp. Med. 203: 2865-2877.
67. Zahn, R. C., M. D. Rett, M. Li, H. Tang, B. Korioth-Schmitz, H. Balachandran, R. White, S. Pryputniewicz, N. L. Letvin, A. Kaur, et al. 2010. Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. Blood 115: 3070-3078.